Soleno Therapeutics Faces Class Action Lawsuit Deadline

Investors have until May 5, 2026 to join lawsuit over alleged securities fraud

Published on Mar. 11, 2026

Got story updates? Submit your updates here. ›

Kahn Swick & Foti, LLC has filed a class action lawsuit against Soleno Therapeutics, Inc. on behalf of investors who were adversely affected by alleged securities fraud between March 26, 2025 and November 4, 2025. The lawsuit alleges that Soleno and certain executives failed to disclose material information about potential safety concerns with the company's only commercial product, DCCR, which is used to treat hyperphagia in individuals with Prader-Willi syndrome.

Why it matters

This lawsuit highlights the importance of transparency and full disclosure for publicly traded companies. Investors rely on accurate information to make informed decisions, and allegations of securities fraud can significantly impact a company's reputation and financial standing.

The details

According to the complaint, Soleno and its executives are accused of failing to disclose substantial evidence of potential safety concerns associated with the administration of DCCR, including indications of excessive fluid retention among clinical trial participants. The lawsuit alleges that this information was material and would have impacted the commercial viability and likelihood of success for DCCR.

  • The class action lawsuit covers the period from March 26, 2025 to November 4, 2025.
  • Investors have until May 5, 2026 to apply to be a lead plaintiff in the case.

The players

Kahn Swick & Foti, LLC

A boutique securities litigation law firm that has been ranked among the top 10 firms nationally based on total settlement value.

Charles C. Foti, Jr.

The former Attorney General of Louisiana and a partner at Kahn Swick & Foti, LLC.

Soleno Therapeutics, Inc.

A biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases.

Got photos? Submit your photos here. ›

What they’re saying

“Soleno investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqcm-slno/ to learn more.”

— Lewis Kahn, Managing Partner, Kahn Swick & Foti, LLC (Globe Newswire)

What’s next

The judge in the case will decide on May 5, 2026 whether to appoint a lead plaintiff for the class action lawsuit.

The takeaway

This lawsuit highlights the importance of transparency and full disclosure for publicly traded companies, as investors rely on accurate information to make informed decisions. The allegations of securities fraud against Soleno Therapeutics could have significant implications for the company's reputation and financial standing.